Literature DB >> 8100823

Pharmacological and molecular characterization of intrinsic and acquired doxorubicin resistance in murine tumor cell lines.

B Schott1, D Londos-Gagliardi, C Ries, S Huet, J Robert.   

Abstract

We have studied the pharmacological parameters of doxorubicin resistance in three lines of murine cells selected by long-term culture in the presence of this drug or vincristine. A line originating from rat hepatoma spontaneously presented an intrinsic doxorubicin resistance as compared to the other lines, originating from a rat glioblastoma and from simian-virus-40-transformed mouse hepatocytes. This intrinsic resistance, as well as the doxorubicin resistance exhibited by the vincristine-selected glioblastoma variant, could be entirely attribute to decreased drug accumulation due to drug efflux. In contrast, the doxorubicin-selected variants of the three lines exhibited an intracellular tolerance to this drug. Despite a reduction in drug accumulation when exposed to the same amount of doxorubicin, they accumulated 6-12 times more doxorubicin than wild lines when submitted to equitoxic exposures. Verapamil could restore in these lines the doxorubicin accumulation observed in sensitive lines but could not restore doxorubicin cytotoxicity. Quantitative evaluation of P-glycoprotein expression by Western blotting with the C219 antibody indicated that the wild hepatoma line overexpressed P-glycoprotein by a factor of 5 in comparison with the other wild lines, and that the vincristine-selected glioblastoma variant overexpressed this protein almost as much as the doxorubicin-selected variants. These observations favor the existence of P-glycoprotein-independent mechanisms of doxorubicin resistance, which are added to the classical multidrug-resistant phenotype in doxorubicin-selected highly resistant variant cell lines.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8100823     DOI: 10.1007/bf01686462

Source DB:  PubMed          Journal:  J Cancer Res Clin Oncol        ISSN: 0171-5216            Impact factor:   4.553


  30 in total

1.  Multidrug resistance associated with altered topoisomerase II activity--topoisomerases II as targets for rational drug design.

Authors:  C S Morrow; K H Cowan
Journal:  J Natl Cancer Inst       Date:  1990-04-18       Impact factor: 13.506

2.  Electrophoretic analysis of 248 clinical breast cancer specimens for P-glycoprotein overexpression or gene amplification.

Authors:  D E Merkel; S A Fuqua; A K Tandon; S M Hill; A U Buzdar; W L McGuire
Journal:  J Clin Oncol       Date:  1989-08       Impact factor: 44.544

3.  Relationship between topoisomerase II level and chemosensitivity in human tumor cell lines.

Authors:  A M Fry; C M Chresta; S M Davies; M C Walker; A L Harris; J A Hartley; J R Masters; I D Hickson
Journal:  Cancer Res       Date:  1991-12-15       Impact factor: 12.701

4.  Differential overexpression of three mdr gene family members in multidrug-resistant J774.2 mouse cells. Evidence that distinct P-glycoprotein precursors are encoded by unique mdr genes.

Authors:  S I Hsu; L Lothstein; S B Horwitz
Journal:  J Biol Chem       Date:  1989-07-15       Impact factor: 5.157

5.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

6.  Comparative cytotoxicity, DNA synthesis inhibition and drug incorporation of eight anthracyclines in a model of doxorubicin-sensitive and -resistant rat glioblastoma cells.

Authors:  B Schott; J Robert
Journal:  Biochem Pharmacol       Date:  1989-01-01       Impact factor: 5.858

7.  Non-P-glycoprotein-mediated multidrug resistance in a small cell lung cancer cell line: evidence for decreased susceptibility to drug-induced DNA damage and reduced levels of topoisomerase II.

Authors:  S P Cole; E R Chanda; F P Dicke; J H Gerlach; S E Mirski
Journal:  Cancer Res       Date:  1991-07-01       Impact factor: 12.701

8.  Multiple resistance mechanisms in Chinese hamster cells resistant to 9-hydroxyellipticine.

Authors:  A K Larsen; A Jacquemin-Sablon
Journal:  Cancer Res       Date:  1989-12-15       Impact factor: 12.701

9.  Expression of a multidrug resistance gene in human cancers.

Authors:  L J Goldstein; H Galski; A Fojo; M Willingham; S L Lai; A Gazdar; R Pirker; A Green; W Crist; G M Brodeur
Journal:  J Natl Cancer Inst       Date:  1989-01-18       Impact factor: 13.506

10.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

View more
  1 in total

1.  Inhibition of protein kinase C in multidrug-resistant cells by modulators of multidrug resistance.

Authors:  Y P Hu; J Robert
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.